Federal contract award
75N93020C00053
COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AJ12 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $6.3M |
| Current contract value | $6.3M |
| Potential contract value / ceiling | $19.2M |
| Start date | Sep 1, 2020 |
| Current end date | Apr 30, 2028 |
| Potential end date | Apr 30, 2028 |
| Latest award activity | Aug 3, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 21 of 21 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 3, 2026 | P00020 | $-28.8K | EO14398 TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jul 17, 2026 | P00019 | $0 | EO14398 TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jan 6, 2026 | P00018 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jul 29, 2025 | P00017 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Mar 14, 2025 | P00016 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Sep 4, 2024 | P00015 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jul 11, 2024 | P00014 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Mar 18, 2024 | P00013 | $850.4K | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Sep 6, 2023 | P00012 | $781.4K | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jun 20, 2023 | P00011 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Mar 6, 2023 | P00010 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Sep 16, 2022 | P00009 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jul 19, 2022 | P00008 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| May 31, 2022 | P00007 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Mar 10, 2022 | P00006 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jan 21, 2022 | P00005 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Oct 15, 2021 | P00004 | $0 | EO14042 - COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Aug 20, 2021 | P00003 | $0 | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jul 6, 2021 | P00002 | $180.5K | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Jun 29, 2021 | P00001 | $1.4M | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
| Aug 21, 2020 | 0 | $3.1M | COVID-19. TO DEVELOP AND MANUFACTURE AN INACTIVATED VIRUS VACCINE USING BLOOD PATHOGEN REDUCTION TECHNOLOGY. |
Estimated positioning window
Apr 30, 2027 – Oct 30, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
65/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 65/100. Available recorded signals: 60 points.
- Contract end 2028-04-30 (553 days from calculation)
- +25 points
- 3 historical awards in this buyer and category group
- +10 points
- 21 recorded award transactions
- +10 points
- Latest award action: 2026-08-03
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Apr 8, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Apr 8, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Apr 1, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Apr 1, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 26, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 26, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 20, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 20, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 13, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 13, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Mar 6, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Mar 6, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 27, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 27, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 24, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 24, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 13, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 13, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Feb 4, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Feb 4, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 21, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 21, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 3, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 3, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Jan 3, 2020 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Jan 3, 2020 |
| Swee L. Teo | Contact | teosl@niaid.nih.gov 240-669-5173 | Source | Dec 11, 2019 |
| Brian Madgey | Contact | brian.madgey@nih.gov 240-627-3712 | Source | Dec 11, 2019 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.